Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Ebastine (formerly LAS-W 090; RP-64305; LAS W090; RP64305; Ebast, Ebatin, Ebatrol, Atmos, Ebet, Kestine, KestineLIO) is a long-acting and selective H1-histamine receptor antagonist used for the treatment of allergic conditions. Ebastine has low potential for causing drowsiness. It has a low likelihood of producing CNS side effects because it does not cross the blood–brain barrier (BBB).
Targets |
Histamine H1 receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Cell Assay |
Cell Line: Human follicle dermal papilla cells (HFDPC)
Concentration: 10 ng/mL, 50 ng/mL, 100 ng/mL, 200 ng/mL, 500 ng/mL Incubation Time: 24 hours, 48 hours Result: The proliferative activity in cells was significantly enhanced. |
||
Animal Protocol |
|
||
References |
|
Molecular Formula |
C32H39NO2
|
|
---|---|---|
Molecular Weight |
469.66
|
|
Exact Mass |
469.3
|
|
Elemental Analysis |
C, 81.83; H, 8.37; N, 2.98; O, 6.81
|
|
CAS # |
90729-43-4
|
|
Related CAS # |
Ebastine-d5; 1216953-13-7
|
|
Appearance |
Solid powder
|
|
SMILES |
CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
|
|
InChi Key |
MJJALKDDGIKVBE-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
|
|
Chemical Name |
4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1292 mL | 10.6460 mL | 21.2920 mL | |
5 mM | 0.4258 mL | 2.1292 mL | 4.2584 mL | |
10 mM | 0.2129 mL | 1.0646 mL | 2.1292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05815602 | Recruiting | Drug: Ebastine Drug: Duspatalin |
IBS - Irritable Bowel Syndrome IBS |
Guy Boeckxstaens | March 30, 2023 | Phase 3 |
NCT01908465 | Completed | Drug: Ebastine Drug: Placebo |
Irritable Bowel Syndrome (IBS) | KU Leuven | November 2013 | Phase 4 |
NCT01144832 | Completed | Drug: ebastine Drug: placebo capsule |
Irritable Bowel Syndrome | KU Leuven | October 2009 | Phase 4 |
Antihistamine effect of ebastine 10 mg. Allergy . 2008 Dec:63 Suppl 89:1-20. td> |
Efficacy of ebastine in patients with seasonal allergic rhinitis. Comparisons of ebastine 10 and 20 mg once-daily (EBA 10; EBA 20) with loratadine 10 mg once-daily (LOR 10) and placebo (PL) for reduction in mean daily reflective total symptoms score during 4 weeks' treatment. Allergy . 2008 Dec:63 Suppl 89:1-20. td> |
Efficacy of ebastine in patients with perennial allergic rhinitis. Comparison of ebastine 10 and 20 mg once-daily (EBA 10; EBA 20) with loratadine 10 mg once-daily (LOR 10) in the reduction of mean daily perennial index after 4 weeks' treatment. Allergy . 2008 Dec:63 Suppl 89:1-20. td> |
Ebastine-induced HFDPC growth. HFDPC were plated in triplicate in 24-well plates for 24 h. Biomed Res Int . 2019 Feb 11:2019:6360503. td> |
Ebastine enhanced the expression of cell cycle regulatory proteins in HFDPC. Biomed Res Int . 2019 Feb 11:2019:6360503. td> |
Ebastine affected apoptosis-related proteins in HFDPC. Biomed Res Int . 2019 Feb 11:2019:6360503. td> |